Selective stimulation of Parkin-mediated mitophagy via the enhancement of its expression and/or mitochondrial translocation using natural or pharmaceutical products may have therapeutic potential for improving mitochondrial quality and survival, suppressing steatosis and preventing mutagenicity in fatty liver disease. The gene discussed is PRKN; the disease is steatosis.